28 January 2003
The influence of etoposide on the distribution of tubulin in human leukemia cell line HL-60.
Alina Grzanka, Dariusz GrzankaMed Sci Monit 2003; 9(1): BR66-69 :: ID: 4781
Abstract
BACKGROUND: In the last decade there has been increasing interest in cytoskeletal research in relation to important process of cell biology. However, after decades of debate many issues remain unsettled. The aim of our study was to estimate the distribution of tubulin in etoposide-induced HL-60 cells and address the question of whether the reorganization of tubulin may be involved in apoptosis. MATERIAL/METHODS: HL-60 cells were incubated with etoposide (0.02-200 mM/L) for 72 hours. Tubulin was estimated by the indirect immunofluorescence method. TRITC-labeled goat anti rabbit IgG was used to label tubulin. RESULTS: Significant changes occurred in cell morphology of and tubulin organization at 200 mM/L etoposide: large cells, brightly labeled for tubulin, in cytoplasm. At 200 uM/L etoposide, we also observed an increase in apoptotic cells with bright staining for tubulin at the site of apoptotic body formations. Cells with features of apoptosis were frequently seen also at 20 mM/L etoposide. The exposure of cells to 0.02, 0.2, or 2 mM/L etoposide did not result in any visible changes in morphology or tubulin organization. Cell size, the number of viable cells, and the percentage of apoptotic cells correlated significantly with the dose of etoposide (p<0.001). CONCLUSIONS: These results indicate that etoposide promotes changes in the distribution of tubulin in HL-60 cells, depending on the dose, and that the reorganization of tubulin seems to be involved in apoptosis
Keywords: Antineoplastic Agents, Phytogenic - pharmacology, Cell Division - drug effects, Dose-Response Relationship, Drug, Etoposide - pharmacology, Fluorescent Antibody Technique, Indirect, HL-60 Cells, Leukemia - drug therapy, Tubulin - metabolism, Tumor Cells, Cultured
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
14 Mar 2024 : Clinical Research
Renal Dysfunction Increases Risk of Adverse Cardiovascular Events in 5-Year Follow-Up Study of Intermediate...Med Sci Monit In Press; DOI: 10.12659/MSM.943956
15 Mar 2024 : Clinical Research
Impact of One-Lung Ventilation on Oxygenation and Ventilation Time in Thoracoscopic Heart Surgery: A Compar...Med Sci Monit In Press; DOI: 10.12659/MSM.943089
14 Mar 2024 : Clinical Research
Differential DHA and EPA Levels in Women with Preterm and Term Births: A Tertiary Hospital Study in IndonesiaMed Sci Monit In Press; DOI: 10.12659/MSM.943895
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952